-
ASH China Voice | Prof. Yajing Zhang: Exploring Frontiers and Synergistic Innovation—A Multidimensional and Strategic Vision for CAR-T Therapy
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.
-
ASH China Voice | Professor Li Zhihui: A New Paradigm for Donor Selection and Transplant Strategies Driven by Hereditary Predisposition Genes
In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected…
-
ASH Expert Insights | Professor Wang Jianxiang: Dual Drivers of FLT3 Ligand and Microclones Enable Precision Upgrading in FLT3-ITD–Negative AML
At the annual meeting of the American Society of Hematology (ASH), research in FLT3-ITD acute myeloid leukemia (AML) delivered important advances for clinical practice. Notably, the latest findings from the QUIWI study series further revealed that, among FLT3-ITD–negative patients, FLT3 ligand (FL) levels and microclonal status can help identify prognostic heterogeneity, offering a new paradigm…
-
ASH Expert Insights | Professor Jun Ma: Transforming FLT3-ITD AML Treatment from Dynamic Management and Optimized Maintenance to Targeted Breakthrough
At this year’s American Society of Hematology (ASH) Annual Meeting, advances in FLT3-ITD acute myeloid leukemia (AML) delivered important clinical insights. From evolving treatment paradigms to optimized maintenance strategies and breakthroughs in targeted therapy, these studies consistently centered on precision medicine, driving care toward greater efficiency and individualization. On site at ASH, Hematology Frontier invited…
-
SIMOS 2025 | From “Following” to “Rewriting”: Prof. Hu Xichun on How China’s Breast Cancer Research Is Poised to Shape Global Guidelines
Editor’s note: From its early focus on “standards, safety and standardized practice” to today’s deep integration of clinical, basic, and translational research, the 8th Shanghai International Medical Oncology Symposium (SIMOS)…
-
2025 ASH Highlights — Three Poster Presentations from the Department of Hematology, 920th Hospital
The 67th American Society of Hematology (ASH) Annual Meeting will be held in Orlando, Florida, USA, from December 6 to 9, 2025. Three studies from the Department of Hematology of…
-
ASH China Voice | Zhijie Wei & Huili Zhu: Letermovir Prophylaxis After Haploidentical HSCT Reduces CMV Infection in Children With Acute Leukemia
Title: Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia Chinese Title : 儿童急性白血病单倍体移植后应用来特莫韦预防CMV感染的疗效和安全性分析 Study Background…
-
ASH China Voice | Prof. Chang Chunkang: Novel JAK/ROCK + BET Inhibitor Regimen Shows Breakthrough Potential in Myelofibrosis
Hematology Frontier: Ruvadicitinib is a JAK/ROCK inhibitor, while TQB3617 is a BET inhibitor. What was the rationale for combining these two agents with distinct mechanisms of action to achieve synergistic…
Connecting Medical Expertise through Media